AVA Bio Defender

Mutation-resistant Viral Defense Technologies

Health Tech & Life Sciences
Active
Seed Jerusalem, Israel Founded 2007
Website ↗ LinkedIn
Last updated 2026-06-18
Total raised
$2.5M
Last: 2010-01
Stage
Seed
Founded
2007
Headcount
3
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences

About

AVA Bio Defender is a biotechnology company specializing in the development of mutation-resistant viral defense with heritable genetic resistance in animals and drug design for human therapy.

Using siRNA technology, the company has developed a highly efficient and sophisticated gene-delivery system that is designed to deliver antiviral protection for all body cells, currently for use in poultry. The company also uses CRISPR technology in animals, which allows directed editing of target genomes.

For humans, AVA Bio Defender develops molecules that can be used as medicine to treat infected people, regardless of the virus’ mutations.

The company’s technologies provide the ability to create resistance to the future mutations of an existing virus, making animals inherently resistant and enabling the development of highly effective medicines for humans.

Funding history · 1 round · $2.5M total

2010-01
$2.5M

Q&A

What is AVA Bio Defender's primary focus?
AVA Bio Defender is a biotechnology company that specializes in developing mutation-resistant viral defense technologies, including heritable genetic resistance in animals and drug design for human therapy.
What technologies does AVA Bio Defender utilize for viral defense?
The company uses siRNA technology to develop a gene-delivery system for antiviral protection in animal cells, specifically for poultry. They also employ CRISPR technology for directed genome editing in animals.
How does AVA Bio Defender address human viral infections?
For humans, AVA Bio Defender develops molecules intended for use as medicine to treat infected individuals, designed to be effective regardless of viral mutations.
When was AVA Bio Defender founded?
AVA Bio Defender was founded in January 2007.
What is the current employee count for AVA Bio Defender?
AVA Bio Defender has 1-10 employees.
What is AVA Bio Defender's total funding to date?
AVA Bio Defender has raised a total of $2,500,000.
When was AVA Bio Defender's last funding round?
AVA Bio Defender's last funding round occurred in January 2010, raising $2,500,000.
What is AVA Bio Defender's current product stage?
AVA Bio Defender's product is currently in the clinical trial stage.
In which sector does AVA Bio Defender primarily operate?
AVA Bio Defender's primary sector is Health Tech & Life Sciences.

Team · 1

Lior Zigler
Founder · Founder & CEO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentDrug Delivery
Technologies
BiologicalsGenesMolecules
Target customers
Agriculture & FoodLivestockPoultryHealthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B

Highlights

1 Patents

Tags

pharmaceuticalsbiotechnologyanimal-healthpoultrybiopharmaceuticaldrug-delivery
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)